drugset / Trial / NCT01259388

A Pilot Study of Lithium in Progressive Multiple Sclerosis

NCT01259388

Phase 1/2 Completed 23 enrolled VA Office of Research and Development
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.

Timeline

Start
2011-05
Primary completion
2015-08
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Carbonate Unknown 150 mg
Subject Lithium Carbonate Unknown 300 mg

Indications